Monoamine Oxidase Inhibitors
"Monoamine Oxidase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414)
| Descriptor ID |
D008996
|
| MeSH Number(s) |
D27.505.519.389.616
|
| Concept/Terms |
Monoamine Oxidase Inhibitors- Monoamine Oxidase Inhibitors
- Inhibitors, Monoamine Oxidase
- Monoamine Oxidase Inhibitor
- Inhibitor, Monoamine Oxidase
- MAO Inhibitors
- Inhibitors, MAO
|
Below are MeSH descriptors whose meaning is more general than "Monoamine Oxidase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Monoamine Oxidase Inhibitors".
This graph shows the total number of publications written about "Monoamine Oxidase Inhibitors" by people in this website by year, and whether "Monoamine Oxidase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 0 | 1 | 1 |
| 1998 | 0 | 2 | 2 |
| 2006 | 1 | 1 | 2 |
| 2008 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2020 | 2 | 0 | 2 |
| 2021 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Monoamine Oxidase Inhibitors" by people in Profiles.
-
Patel P, Pol A, Kalaria D, Date AA, Kalia Y, Patravale V. Microemulsion-based gel for the transdermal delivery of rasagiline mesylate: In vitro and in vivo assessment for Parkinson's therapy. Eur J Pharm Biopharm. 2021 Aug; 165:66-74.
-
Tarpley M, Oladapo HO, Strepay D, Caligan TB, Chdid L, Shehata H, Roques JR, Thomas R, Laudeman CP, Onyenwoke RU, Darr DB, Williams KP. Identification of harmine and ?-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies. Eur J Pharm Sci. 2021 Jul 01; 162:105821.
-
Musa MA, Badisa VLD, Aghimien MO, Eyunni SVK, Latinwo LM. Identification of 7,8-dihydroxy-3-phenylcoumarin as a reversible monoamine oxidase enzyme inhibitor. J Biochem Mol Toxicol. 2021 Feb; 35(2):e22651.
-
Zarmouh NO, Messeha SS, Mateeva N, Gangapuram M, Flowers K, Eyunni SVK, Zhang W, Redda KK, Soliman KFA. The Antiproliferative Effects of Flavonoid MAO Inhibitors on Prostate Cancer Cells. Molecules. 2020 May 11; 25(9).
-
Zarmouh NO, Eyunni SK, Soliman KF. The Benzopyrone Biochanin-A as a reversible, competitive, and selective monoamine oxidase B inhibitor. BMC Complement Altern Med. 2017 Jan 10; 17(1):34.
-
Kowalko JE, Rohner N, Rompani SB, Peterson BK, Linden TA, Yoshizawa M, Kay EH, Weber J, Hoekstra HE, Jeffery WR, Borowsky R, Tabin CJ. Loss of schooling behavior in cavefish through sight-dependent and sight-independent mechanisms. Curr Biol. 2013 Oct 07; 23(19):1874-83.
-
Mazzio E, Deiab S, Park K, Soliman KF. High throughput screening to identify natural human monoamine oxidase B inhibitors. Phytother Res. 2013 Jun; 27(6):818-28.
-
Mellman T, Lydiard RB. Posttraumatic stress disorder: characteristics and treatment. J Clin Psychiatry. 2008 Jan; 69(1):e2.
-
Wood CE, Appt SE, Clarkson TB, Franke AA, Lees CJ, Doerge DR, Cline JM. Effects of high-dose soy isoflavones and equol on reproductive tissues in female cynomolgus monkeys. Biol Reprod. 2006 Sep; 75(3):477-86.
-
Csoka AB, Shipko S. Persistent sexual side effects after SSRI discontinuation. Psychother Psychosom. 2006; 75(3):187-8.